JP2021530989A5 - - Google Patents
Info
- Publication number
- JP2021530989A5 JP2021530989A5 JP2021500868A JP2021500868A JP2021530989A5 JP 2021530989 A5 JP2021530989 A5 JP 2021530989A5 JP 2021500868 A JP2021500868 A JP 2021500868A JP 2021500868 A JP2021500868 A JP 2021500868A JP 2021530989 A5 JP2021530989 A5 JP 2021530989A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- igg1
- domain monomer
- monomer
- polypeptide
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696711P | 2018-07-11 | 2018-07-11 | |
| US62/696,711 | 2018-07-11 | ||
| PCT/US2019/041306 WO2020014419A2 (en) | 2018-07-11 | 2019-07-11 | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530989A JP2021530989A (ja) | 2021-11-18 |
| JP2021530989A5 true JP2021530989A5 (https=) | 2022-07-20 |
| JPWO2020014419A5 JPWO2020014419A5 (https=) | 2022-07-20 |
Family
ID=69141681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500868A Withdrawn JP2021530989A (ja) | 2018-07-11 | 2019-07-11 | ＰＤ−Ｌ１を標的とした改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210147549A1 (https=) |
| EP (1) | EP3820998A4 (https=) |
| JP (1) | JP2021530989A (https=) |
| KR (1) | KR20210044782A (https=) |
| CN (1) | CN112996910A (https=) |
| AU (1) | AU2019299935A1 (https=) |
| BR (1) | BR112021000383A2 (https=) |
| CA (1) | CA3106108A1 (https=) |
| IL (1) | IL280038A (https=) |
| MX (1) | MX2021000281A (https=) |
| WO (1) | WO2020014419A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024219897A1 (ko) * | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| WO2024219894A1 (ko) * | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| CN117736329B (zh) * | 2023-12-25 | 2024-11-12 | 华润生物医药有限公司 | 抗pd-1抗体及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20201595T1 (hr) * | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| AU2013229488B2 (en) * | 2012-03-08 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JP2017518965A (ja) * | 2014-05-02 | 2017-07-13 | モメンタ ファーマシューティカルズ インコーポレイテッ | エンジニアリングされたＦｃ構築物に関連する組成物および方法 |
| JP6744313B2 (ja) * | 2015-01-02 | 2020-08-26 | ダイアックス コーポレーション | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| PH12017501857B1 (en) * | 2015-06-16 | 2024-01-17 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
| CA3000386A1 (en) * | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| WO2017151971A2 (en) * | 2016-03-02 | 2017-09-08 | Momenta Pharmaceuticals, Inc. | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS |
| CN108779180B (zh) * | 2016-03-23 | 2020-10-16 | 迈博斯生物医药(苏州)有限公司 | 新型抗-pd-l1抗体 |
| BR112018074056A2 (pt) * | 2016-05-23 | 2019-03-06 | Momenta Pharmaceuticals, Inc. | composições e métodos relacionados a construtos de fc manipulados |
| WO2018009466A1 (en) * | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| WO2018115262A1 (en) * | 2016-12-23 | 2018-06-28 | Innate Pharma | Heterodimeric antigen binding proteins |
-
2019
- 2019-07-11 BR BR112021000383-5A patent/BR112021000383A2/pt not_active IP Right Cessation
- 2019-07-11 JP JP2021500868A patent/JP2021530989A/ja not_active Withdrawn
- 2019-07-11 CN CN201980059583.6A patent/CN112996910A/zh active Pending
- 2019-07-11 MX MX2021000281A patent/MX2021000281A/es unknown
- 2019-07-11 US US17/259,067 patent/US20210147549A1/en not_active Abandoned
- 2019-07-11 KR KR1020217004246A patent/KR20210044782A/ko not_active Ceased
- 2019-07-11 AU AU2019299935A patent/AU2019299935A1/en not_active Abandoned
- 2019-07-11 CA CA3106108A patent/CA3106108A1/en active Pending
- 2019-07-11 EP EP19833243.9A patent/EP3820998A4/en not_active Withdrawn
- 2019-07-11 WO PCT/US2019/041306 patent/WO2020014419A2/en not_active Ceased
-
2021
- 2021-01-10 IL IL280038A patent/IL280038A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532085A5 (https=) | ||
| JP2021530498A5 (https=) | ||
| JP2021530989A5 (https=) | ||
| RU2019124709A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| DE50210328D1 (de) | Bispezifisches anti-cd28 antikörper-molekül | |
| JP2020514301A5 (https=) | ||
| HRP20201517T1 (hr) | Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123 | |
| ATE452147T1 (de) | Antikörper mit korrigierten cdr | |
| NZ597168A (en) | Dual variable domain immunoglobin and uses thereof | |
| JP2021531756A5 (https=) | ||
| RU2014100111A (ru) | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| DE602004021702D1 (de) | Humanisierter antikörper gegen cd4 mit immunsuppressiven merkmalen | |
| JP2019528240A5 (https=) | ||
| PT1699826E (pt) | Domínios de imunoglobulina sintética com propriedades de ligação construídos em regiões da molécula diferentes das regiões determinantes de complementaridade | |
| ATE479710T1 (de) | Bispezifische antikörper | |
| NZ589434A (en) | Dual variable domain immunoglobulins and uses thereof | |
| JP2021531268A5 (https=) | ||
| ATE490983T1 (de) | Humane antikörper gegen das humane glycoprotein vi und deren verwendung | |
| IL307938B1 (en) | Anti-c-met antibody drug conjugates | |
| WO2011064257A3 (de) | Monospezifische polypeptidreagenzien | |
| CA3261607A1 (en) | Antibody-drug combinations that bind to CDCP1 and their uses | |
| JPWO2020014413A5 (https=) | ||
| PE20231953A1 (es) | Anticuerpos multiespecificos y combinaciones de anticuerpos | |
| JPWO2020014526A5 (https=) |